<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203590</url>
  </required_header>
  <id_info>
    <org_study_id>3939366</org_study_id>
    <nct_id>NCT03203590</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients</brief_title>
  <official_title>Oral Navelbine Carboplatin Versus Gefitinib Neoadjuvant Therapy for Resectable EGFR Mutation Positive Stage Ⅱ-ⅢA NSCLC, Prospective, Randomized, Multicenter, Phase Ⅲ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maoming Affiliated Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency and safety of Gefitinib Neoadjuvant&#xD;
      Therapy and Oral Navelbine Carboplatin Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢA NSCLC&#xD;
      patients with EGFR mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the most common cause of cancer mortality in men and women in the world. LACE&#xD;
      meta analysis shows that the 5-year survival rate of post-operation chemotherapy group rose&#xD;
      by 5.4%, therefore, adjuvant chemotherapy has been the main treatment after surgery according&#xD;
      to National Comprehensive Cancer Network (NCCN) Guideline. But patients have poor compliance&#xD;
      due to physical condition after surgery. Compared with adjuvant chemotherapy, neoadjuvant&#xD;
      therapy has better patient compliance and tolerance.Targeted therapy, with milder side effect&#xD;
      compared with chemotherapy, may be a promising choice to treat NSCLC previously. But to date,&#xD;
      there is no enough evidence to support the efficacy and safety of neoadjuvant targeted&#xD;
      therapy in patients with EGFR mutation.The purpose of this study is to evaluate the&#xD;
      efficiency and safety of Gefitinib Neoadjuvant Therapy vs Oral Navelbine Carboplatin&#xD;
      Neoadjuvant Therapy for Resectable NSCLC patients harboring EGFR mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard uptake value</measure>
    <time_frame>1 week before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor reduction rate</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mediastinal lymph nodes clearance</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Within 1 month after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Within 1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality rate</measure>
    <time_frame>Within 1 month after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>2-year Disease-Free Survival</condition>
  <arm_group>
    <arm_group_label>Oral Navelbine + Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Navelbine + Carboplatin</intervention_name>
    <description>The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.</description>
    <arm_group_label>Oral Navelbine + Carboplatin</arm_group_label>
    <other_name>Vinorelbine</other_name>
    <other_name>Carboplat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic diagnosis of non small cell lung cancer, Stage Ⅱ-ⅢA before treatment&#xD;
&#xD;
          -  EGFR Gene mutated&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  liver, kidney and bone marrow are functional healthy，WBC&gt;4.0×109/L，PLT&gt;100×109/L&#xD;
             Hb&gt;10g/dL;Cr&lt;1.8mg/dL，bilirubin&lt;1.5mg/dL，GPT&lt;1.5 upper limit of normal&#xD;
&#xD;
          -  No vital systems dysfunction or malnutrition&#xD;
&#xD;
          -  No other malignant diseases in 5 years（except non melanoma or Cervical carcinoma in&#xD;
             situ）&#xD;
&#xD;
          -  Have never accepted radiation therapy、overall chemotherapy or biotherapy&#xD;
&#xD;
          -  Know the whole protocol，Voluntary participate and sign a consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor has violated the surrounding tissue organs（T4）&#xD;
&#xD;
          -  Preoperative have evidence of distant metastasis including the contralateral&#xD;
             mediastinal lymph nodes&#xD;
&#xD;
          -  Arrhythmia need anti-arrhythmic treatment（except for β-blockers or&#xD;
             digoxin），Symptomatic coronary artery disease and myocardial ischemia (myocardial&#xD;
             infarction) in the past 6 months or more than NYHA class II congestive heart failure&#xD;
&#xD;
          -  Adverse drug control severe hypertension&#xD;
&#xD;
          -  Moderate to severe proteinuria&#xD;
&#xD;
          -  History of HIV infection or activity of chronic hepatitis b or hepatitis c, or other&#xD;
             active clinical severe infection&#xD;
&#xD;
          -  Cachexy,organ function decompensation&#xD;
&#xD;
          -  History of chest radiotherapy&#xD;
&#xD;
          -  Not fully control the eye inflammation&#xD;
&#xD;
          -  Epilepsy patients needed treatment（such as Steroids or antiepileptic cure）&#xD;
&#xD;
          -  Interstitial pneumonia&#xD;
&#xD;
          -  Drug abuse and medical, psychological or social conditions may interfere with the&#xD;
             patients involved in the research or have an impact on the results of evaluation&#xD;
&#xD;
          -  Known or suspected to study drug allergy or to give any drug allergies associated with&#xD;
             this test&#xD;
&#xD;
          -  Any unstable situation or may endanger the patient safety and compliance&#xD;
&#xD;
          -  Fertility and pregnancy or lactation women, and have not been sufficient precautions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guowei Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guowei Ma, MD</last_name>
    <phone>13501546669</phone>
    <email>magw@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianping Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guowei Ma, MD</last_name>
      <email>magw@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Guowei Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinming Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maoming Affiliated Hospital of Southern Medical University</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <zip>525000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiang Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guangsuo Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Guowei Ma</investigator_full_name>
    <investigator_title>Professor,Chief Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

